Celltrion Says New Data Prove Remsima SC Is A ‘Biobetter’
Subcutaneous Infliximab Shows Improved Outcomes Compared To Intravenous Version
Executive Summary
Celltrion says new data show that its Remsima SC subcutaneous infliximab biosimilar produces “statistically greater improvements in clinical outcomes” for rheumatoid arthritis patients compared to intravenous infliximab.
You may also be interested in...
Celltrion Calls For Harmonized Approach To ‘Biobetters’
A standardized, globally-accepted approach to ‘biobetters’ – biosimilars that offer improvements over the original reference drug – is needed to reduce trial duplication and allow products to come to market more quickly, Celltrion tells Generics Bulletin, at the same time as the company published data showing the benefits of its Remsima SC unique subcutaneous formulation of infliximab.
Celltrion’s Remsima SC Biosimilar Starts Strong In EU5 Countries
Celltrion is capitalizing on the earlier strength of its intravenous Remsima formulation to make waves with its innovative subcutaneous version, according to the results of a new study sampling nearly 250 gastroenterologists in EU5 countries.
Celltrion Healthcare Gears Up For Infliximab SC Launch
As Celltrion Healthcare prepares to roll out Remsima SC, its subcutaneous infliximab, in Europe – starting in the UK and Germany – Celltrion Healthcare’s UK commercial head, Matthew Eddleston, speaks to Generics Bulletin about how the innovative biosimilar will be positioned in the market.